# Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors

> **NCT04504942** · PHASE2 · COMPLETED · sponsor: **CytoDyn, Inc.** · enrollment: 16 (actual)

## Conditions studied

- Solid Tumor, Adult

## Interventions

- **DRUG:** Leronlimab

## Key facts

- **NCT ID:** NCT04504942
- **Lead sponsor:** CytoDyn, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-01
- **Primary completion:** 2021-11-07
- **Final completion:** 2025-01-27
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2026-01-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04504942

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04504942, "Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors". Retrieved via MORVS 2026-10-10 from https://api.morvs.ai/clinical/NCT04504942. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*